Kristen Hallam on Muck Rack

Kristen Hallam

Verified
As seen in: Bloomberg News, Bloomberg Businessweek, The Boston Globe, New Zealand Herald, Buffalo News, Accounting Today, Salt Lake Tribune, Livemint and 69 more
Covers:  science, health policy, biotechnology, mergers & acquisitions, health, pharmaceutics
Doesn't Cover: clinical trial initiation, new product launches

@BloombergNews health editor in London. @NorthwesternU alum, @AHCJ member. Email: khallam@bloomberg.net. RTs & links not endorsements.

Boston Scientific to Buy Endoscopy Company in $210M Deal

bloomberg.com — Boston Scientific Corp. agreed to buy EndoChoice Holdings Inc. for about $210 million to expand its endoscopy business. The $8-a-share purchase price is almost double EndoChoice's closing price of $4.22 as of Monday. The deal is expected to complete in the fourth quarter, Marlborough, Massachusetts-based Boston Scientific said Tuesday in a statement.

AstraZeneca Withdraws EU Application for Ovarian-Cancer Therapy

bloomberg.com — AstraZeneca Plc said it is withdrawing an application for European approval for an ovarian-cancer medicine following disagreement with regulatory authorities. The decision won't affect the ongoing development of the treatment, called cediranib, the Cambridge, England-based company said today in an e-mailed statement.

Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO

Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO

bloomberg.com — GlaxoSmithKline Plc's new chief executive looks a lot like other bosses at large pharmaceutical companies: a graduate of Oxford, white, with worldwide experience managing thousands of employees. There is, though, one big difference: She's not a man.

Crops Would Eclipse Drugs at Bayer After Monsanto Deal: Chart

bloomberg.com — The balance seems to be shifting at Bayer AG. By buying Monsanto Co., the German company would see its crop-science unit surpass pharmaceuticals in sales. The health-care business generated about 44 percent of sales last year, more than any other Bayer division.

Horizon Pharma Buys Rare-Disease Company Raptor for $800 Million

Departing Pharma CEOs Leave Waning Sales for Successors to Solve

bloomberg.com — Another pharmaceutical chief executive is riding off into the sunset, the latest departure in an industry struggling to invent new medicines amid unprecedented pricing pressure. Novo Nordisk A/S's Lars Rebien Soerensen, chosen by Harvard Business Review as the world's best-performing CEO last year, is retiring from the world's biggest maker of insulin, the company said Thursday.

Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

bloomberg.com — Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment. Cell and gene therapy development will no longer be housed in a separate division, the Basel, Switzerland-based company said Wednesday in an e-mailed statement.

Mylan to reduce EpiPen costs as political pressure mounts

therolladailynews.com — xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx

Mylan to reduce EpiPen costs as political pressure mounts

washingtontimesreporter.com — xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxx
More Articles →
Sep 28, 2016

RT @katie_thomas: When a big patient group decided to speak out about high drug prices, some pharma donors pushed back. https://t.co/bLagcbjQsI

Sep 28, 2016

I got a pitch today about a company called Totally Plc. I thought it was, like, totally not real. But it totally was.

Sep 28, 2016

Took my kid to the GP. Three people I told about it assumed the GP was male. She wasn't. Are most GPs male?

Sep 28, 2016

Maybe they're factoring in NJ suburbs. Because who doesn't want to live in The Great State of New Jersey?  https://twitter.com/rocks_david/status/781102216346214400 

Sep 28, 2016

Facebook founder’s science group hires AstraZeneca board member  http://bloom.bg/2dqArbW  via @technology $AZN by @ketakigokhale

Sep 27, 2016

RT @CarolineYLChen: When I wrote this #ZIKA story w @SmithMarkets, we thought Congress would fund bill on return. But nope, still no $$$ https://t.co/OqG8TlSbyH

Sep 27, 2016

RT @Loftus: Goldman ranks drug companies' reliance on pricing: Horizon, Jazz at high end; Lilly, Celgene, Gilead low end $HZNP… https://t.co/wx7Q0IBSDD

Sep 27, 2016

@jordanrau Only those who text while walking. Which in London is 80 percent of the population.


Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio